---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-087275"
form_type: "8-K"
ticker: "GPCR"
cik: "0001888886"
company_name: "Structure Therapeutics Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:19:02.981208+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Structure Therapeutics Q2 net loss $26M; cash $927M; GSBR-1290 Phase 2b on track Q4 2024

## Summary
- Q2 2024 net loss $26.0M vs $23.3M in Q2 2023; R&D expenses $22.1M, G&A $11.3M.
- Cash, equivalents and short-term investments $927.1M expected to fund operations through at least 2027.
- GSBR-1290 Phase 2b obesity study on track to initiate in Q4 2024; Phase 2a showed 6.2% placebo-adjusted weight loss at 12 weeks.
- Amylin receptor agonist development candidate expected to be selected in Q4 2024; GIPR candidate expected H1 2025.
- Phase 1 trial of LTSE-2578 (LPA1R antagonist for IPF) initiated in June 2024.

## SEC filing metadata
- accession: 0001104659-24-087275
- form_type: 8-K
- ticker: GPCR
- cik: 0001888886
- company_name: Structure Therapeutics Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1888886/000110465924087275/0001104659-24-087275-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1888886/000110465924087275/tm2421118d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-087275
- JSON: https://secwatch.observer/filing/0001104659-24-087275.json
- Plain text: https://secwatch.observer/filing/0001104659-24-087275.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.